Dyslipidemia

A new AHA statement highlights the benefits of lipoprotein apheresis for familial hypercholesterolemia and urges broader access to the underutilized therapy.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Rahul Aggarwal, MD, discusses how the VICTORION-1 PREVENT trial eligibility criteria apply to the general US population.

The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!

Elucid has received 510(k) clearance for its PlaqueIQ™ imaging analysis software to help physicians diagnose cardiovascular disease.

Subclinical atherosclerosis burden and its progression are independently linked to the risk of death from any cause in asymptomatic individuals.

Family Heart Foundation announces the launch of Cholesterol Connect, a program that provides free at-home lipid screening and personalized support.

A comparison of the PALISADE and BALANCE trials, with commentary from a leading cardiologist, as the community nears a potential approval in FCS.

Expert clinical consensus from the National Lipid Association finds ApoB testing is useful to stratify ASCVD risk more accurately than LDL-C.

The approval to GE Healthcare's cyclotron-produced radioactive diagnostic drug provides another option to adequately identify significant coronary artery disease.

Christie Ballantyne, MD, discusses non-statin therapies, both approved and in development, for managing dyslipidemias from the floor of the 2024 Family Heart Global Summit.

A randomized trial suggests gefarnate significantly reduces triglycerides and LDL-C in older adults on statins with residual hypertriglyceridemia.

The joint guidelines address evidence on the management of patients before, during, and after noncardiac surgery since the last update in 2014.

Announced on September 24, 2024, the approval marks the second treatment approved by the FDA for Niemann-Pick disease type C within one week.

A Q&A with Nihar Desai, MD, on the PROMPT-Lipid trial and the potential of advancing technology for improving patient care in pragmatic ways.

Nihar Desai, MD, discusses the results of the PROMPT-Lipid trial while on-site at the 2024 Family Heart Global Summit.

Laurence Sperling, MD, discusses his presentation from the 2024 Family Heart Global Summit examining public health efforts for prevention of cardiovascular disease.

Arimoclomol, in combination with miglustat, is approved to treat neurological symptoms associated with NPC in adults and children aged ≥2 years.

Lp(a) ordering remains low in patients at risk for ASCVD, particularly non-Hispanic Black or Hispanic individuals in socioeconomically disadvantaged neighborhoods.

A new study revealed those who consume a moderate amount of coffee or caffeine had a 48.1% and 40.7% reduced risk for developing cardiometabolic multimorbidity.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.

In this edition of the APAC Recap, Erin Pardee, PA-C, discusses the American Society of Preventive Cardiology 2024 Congress on CVD Prevention with Viet Le, DMSc, PA-C.

The agency's designation was granted to plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.

The August 2024 cardiology month in review highlights critical data from the European Society of Cardiology Congress 24 and the latest updates on finerenone.

ESC 2024: Phase 3 PALISADE trial shows plozasiran significantly lowers triglycerides and pancreatitis risk in FCS; NDA planned by year-end.

Kausik Ray, MD, MPhil, discusses the results of the INTERASPIRE study and how it improves our understanding of the effects of elevated Lp(a).

A single blood test using hsCRP, LDL-C, and Lp(a) levels can predict cardiovascular risk for women up to 30 years, emphasizing personalized care.

Kausik Ray, MD, discusses what trials and new data in lipidology he is most looking forward to from the upcoming ESC Congress.

Intensive lipid-lowering treatment regimens were linked to a notable reduction in three-point MACE risk and ACS recurrence versus background statin therapy.

Modifiable risk factors, including elevated HbA1C and blood pressure, were linked to a higher risk of DME development in a large multicenter database.